All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause

Journal of Steroid Biochemistry and Molecular Biology

Volumn 145, Issue , 2015, Pages 133-138

  Labrie, Fernand ^a  

^a Endoceutics Inc   (Canada)

Author keywords

Androgens; Breast cancer; Dehydroepiandrosterone; Estrogens; Intracrinology; Menopause

Indexed keywords

ANDROGEN; ESTRADIOL; PRASTERONE; SEX HORMONE; AROMATASE INHIBITOR; ESTROGEN; HYDROCORTISONE; PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID;

ARTICLE; DRUG EFFICACY; DRUG MECHANISM; ENDOMETRIUM; ESTRADIOL BLOOD LEVEL; ESTROGEN RELEASE; FEMALE; HORMONAL REGULATION; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; REGULATORY MECHANISM; STEROIDOGENESIS; VAGINA ATROPHY; BIOSYNTHESIS; BREAST TUMOR; METABOLISM; OVARY; SECRETION (PROCESS);

AROMATASE INHIBITORS; BREAST NEOPLASMS; DEHYDROEPIANDROSTERONE; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; HUMANS; HYDROCORTISONE; MENOPAUSE; OVARY; PROGESTERONE; STEROIDS;

EID: 84915817059     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2014.06.001     Document Type: Review

References (50)

1. D.F. Archer Drospirenone-containing hormone therapy for postmenopausal women. Perspective on current data J. Reprod. Med. 52 2007 159 164
2. A. Pines, D.W. Sturdee, A.H. MacLennan, H.P. Schneider, H. Burger, and A. Fenton The heart of the WHI study: time for hormone therapy policies to be revised Climacteric 10 2007 267 269
3. W.H. Utian, D. Shoupe, G. Bachmann, J.V. Pinkerton, and J.H. Pickar Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate Fertil. Steril. 75 2001 1065 1079
4. W.H.O. Scientific Group Research on the menopause in the 1990s WHO technical report series No 866 1996 World Health Organization Geneva
5. F. Labrie Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy Nat. Clin. Pract. Endocrinol. Metabol. 3 2007 584 593
6. N. Panay, and E. Kalu Management of premature ovarian failure Best Pract. Res. Clin. Obstet. Gynaecol. 23 2009 129 140
7. J.A. Simon, K.Z. Reape, S. Wininger, and H. Hait Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healty postmenopausal women Fertil. Steril. 90 2008 1132 1138
8. NAMS: Professional Education Committee Overview of menopause and aging Menopause Practice: A Clinician's Guide 2007 The North American Menopause Society Mayfield Heights (OH) 9 17
9. N.L. Kleinman, N.J. Rohrbacker, A.G. Bushmakin, J. Whiteley, W.D. Lynch, and S.N. Shah Direct and indirect costs of women diagnosed with menopause symptoms J. Occup. Environ. Med. 55 2013 465 470
10. E.B. Gold, B. Sternfeld, J.L. Kelsey, C. Brown, C. Mouton, and N. Reame Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age Am. J. Epidemiol. 152 2000 463 473
11. E. Anderson, S. Hamburger, J.H. Liu, and R.W. Rebar Characteristics of menopausal women seeking assistance Am. J. Obstet. Gynecol. 156 1987 428 433
12. R.E. Williams, K.B. Levine, L. Kalilani, J. Lewis, and R.V. Clark Menopause-specific questionnaire assessment in US population-based study shows negative impact on health-related quality of life Maturitas 62 2009 153 159
13. F. Labrie, C. Martel, and J. Balser Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary? Menopause 18 2011 30 43
14. C. Labrie, A. Bélanger, and F. Labrie Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate Endocrinology 123 1988 1412 1417
15. F. Labrie Intracrinology Mol. Cell. Endocrinol. 78 1991 C113 C118
16. F. Labrie DHEA after menopause-sole source of sex steroids and potential sex steroid deficiency treatment Menopause Management 19 2010 14 24
17. F. Labrie, A. Dupont, and A. Bélanger Complete androgen blockade for the treatment of prostate cancer V.T. de Vita, S. Hellman, S.A. Rosenberg, Important Advances in Oncology 1985 J.B. Lippincott Philadelphia 193 217
18. F. Labrie, V. Luu-The, A. Bélanger, S.-X. Lin, J. Simard, and C. Labrie Is DHEA a hormone? Starling review J. Endocrinol. 187 2005 169 196
19. V. Luu-The Assessment of steroidogenic pathways that do not require testosterone as intermediate Horm. Mol. Biol. Clin. Invest. 5 2011 161 165
20. C. Labrie, J. Simard, H.F. Zhao, A. Bélanger, G. Pelletier, and F. Labrie Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate Endocrinology 124 1989 2745 2754
21. F. Labrie, J. Simard, V. Luu-The, A. Bélanger, and G. Pelletier Structure, function and tissue-specific gene expression of 3é-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase enzymes in classical and peripheral intracrine steroidogenic tissues J. Steroid Biochem. Mol. Biol. 43 1992 805 826
22. F. Labrie, Y. Sugimoto, V. Luu-The, J. Simard, Y. Lachance, and D. Bachvarov Structure of human type II 5 alpha-reductase gene Endocrinology 131 1992 1571 1573
23. Y. Labrie, F. Durocher, Y. Lachance, C. Turgeon, J. Simard, and C. Labrie The human type II 17β-hydroxysteroid dehydrogenase gene encodes two alternatively-spliced messenger RNA species DNA Cell Biol. 14 1995 849 861
24. V. Luu-The, Y. Zhang, D. Poirier, and F. Labrie Characteristics of human types 1, 2 and 3 17b-hydroxysteroid dehydrogenase activities: oxidation-reduction and inhibition J. Steroid Biochem. Mol. Biol. 55 1995 581 587
25. Labrie F, Simard J, Luu-The V, Bélanger A, Pelletier G, Morel Y, et al.; The 3β-hydroxysteroid dehydrogenase/isomerase gene family: lessons from type II 3β-HSD congenital deficiency. Signal Transduction in Testicular Cells, Ernst Schering Research Foundation Workshop. 1996; Suppl. 2:185-218.
26. F. Labrie, V. Luu-The, S.X. Lin, C. Labrie, J. Simard, and R. Breton The key role of 17β-HSDs in sex steroid biology Steroids 62 1997 148 158
27. P.M. Baxendale, M.J. Reed, and V.H. James Inability of human endometrium or myometrium to aromatize androstenedione J. Steroid Biochem. 14 1981 305 306
28. S.E. Bulun, Z. Lin, G. Imir, S. Amin, M. Demura, and B. Yilmaz Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment Pharmacol. Rev. 57 2005 359 383
29. K. Toda, E.R. Simpson, C.R. Mendelson, Y. Shizuta, and M.W. Kilgore Expression of the gene encoding aromatase cytochrome P450 (CYP19) in fetal tissues Mol. Endocrinol. 8 1994 210 217
30. H. Bundgaard P. Krogsgaard-Larsen, H. Bundgaard, Design and Application of Prodrugs (In a Texbook of Drug Design and Development) 1991 Harwood Academic Publishers GmbH C Chur, Switzerland
31. J.C. Havelock, W.E. Rainey, K.D. Bradshaw, and B.R. Carr The post-menopausal ovary displays a unique pattern of steroidogenic enzyme expression Hum. Reprod. 21 2006 309 317
32. M.E. Baker Co-evolution of steroidogenic and steroid-inactivating enzymes and adrenal and sex steroid receptors Mol. Cell. Endocrinol. 215 2004 55 62
33. F. Labrie, and C. Labrie DHEA and intracrinology at menopause, a positive choice for evolution of the human species Climacteric 16 2013 205 213
34. F. Labrie, A. Bélanger, P. Bélanger, R. Bérubé, C. Martel, and L. Cusan Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women J. Ster. Biochem. Mol. Biol. 99 2006 182 188
35. C.B. Hammond, F.R. Jelovsek, K.L. Lee, W.T. Creasman, and R.T. Parker Effects of long-term estrogen replacement therapy. II. Neoplasia Am. J. Obstet. Gynecol. 133 1979 537 547
36. D.C. Smith, R. Prentice, D.J. Thompson, and W.L. Herrmann Association of exogenous estrogen and endometrial carcinoma N. Engl. J. Med. 293 1975 1164 1167
37. The Writing Group for the Trial Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. The writing group for the PEPI trial JAMA 275 1996 370 375
38. C. Longcope, C. Franz, C. Morello, R. Baker, and C.C. Johnston Jr. Steroid and gonadotropin levels in women during the peri-menopausal years Maturitas 8 1986 189 196
39. H.G. Burger, E.C. Dudley, J. Cui, L. Dennerstein, and J.C. Hopper A prospective longitudinal study of serum testosterone dehydroepiandrosterone sulfate and sex hormone binding globulin levels through the menopause transition J. Clin. Endocrin. Metab. 85 2000 2832 2838
40. G. Rannevik, S. Jeppsson, O. Johnell, B. Bjerre, Y. Laurell-Borulf, and L. Svanberg A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density Maturitas 21 1995 103 113
41. F. Labrie, D. Archer, C. Bouchard, M. Fortier, L. Cusan, and J.L. Gomez Intravaginal dehydroepiandrosterone (prasterone), a physiological and highly efficient treatment of vaginal atrophy Menopause 16 2009 907 922
42. F. Labrie, D. Archer, C. Bouchard, M. Fortier, L. Cusan, and J.L. Gomez Effect on intravaginal dehydroepiandrosterone (prasterone) on libido and sexual dysfunction in postmenopausal women Menopause 16 2009 923 931
43. M.A. Pessina, R.F. Hoyt Jr.; I. Goldstein, and A.M. Traish Differential effects of estradiol, progesterone, and testosterone on vaginal structural integrity Endocrinology 147 2006 61 69
44. G. Pelletier, J. Ouellet, C. Martel, and F. Labrie Androgenic action of dehydroepiandrosterone (DHEA) on nerve density in the ovariectomized rat vagina J. Sex. Med. 10 2013 1908 1914
45. F. Labrie, D. Archer, C. Bouchard, M. Fortier, L. Cusan, and J.L. Gomez Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration Menopause 16 2009 897 906
46. F. Labrie, L. Cusan, J.L. Gomez, I. Côté, R. Bérubé, and P. Bélanger Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women J. Ster. Biochem. Mol. Biol. 111 2008 178 194
47. F. Labrie, L. Cusan, J.L. Gomez, I. Côté, R. Bérubé, and P. Bélanger Corrigendum to: effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women J. Steroid Biochem. Mol. Biol. 112 2008 169
48. F. Labrie, C. Martel, R. Berube, I. Cote, C. Labrie, and L. Cusan Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens J. Steroid Biochem. Mol. Biol. 138 2013 359 367
49. M. Eugster-Hausmann, J. Waitzinger, and D. Lehnick Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets Climacteric 13 2010 219 227
50. F. Labrie, A. Bélanger, P. Bélanger, R. Bérubé, C. Martel, and L. Cusan Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women J. Steroid Biochem. Mol. Biol. 99 2006 182 188